Company intelligence / Profile preview

Seragen, Inc.

Hopkinton/Westerly, Massachusetts/Rhode Island, United Statesceragemus.com ↗

Ownership: Private
Development stage: Commercial

Overview

Seragen developed recombinant fusion proteins targeting specific cell surface receptors for cancer and immune-related diseases. Its lead product Ontak® (denileukin diftitox) was approved for cutaneous T-cell lymphoma after the company's acquisition by Ligand. Earlier clinical results showed statistical significance in psoriasis trials; other programs were discontinued or outlicensed.

Therapeutic areas: OncologyDermatologyCardiovascularEndocrinology
Modalities: Fusion proteinsRecombinant protein therapeutics
Industry: Biotech

Drug pipeline

1 asset

denileukin diftitox

Commercial

Indications: Cutaneous T-cell lymphoma

Partnerships

Eli Lilly & Co.U.S. Surgical Corp.

Beyond the preview

Go deeper on Seragen, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seragen, Inc..

Explore the full profile